CEL-SCI Corporation (CVM) Cash Flow Statement

NYSE American: CVMOperating cash, capex, free cash flow and buybacks.

Where CVM’s cash came from and went, FY2025

September 30, 2025 · U.S. dollars
Cash from operations
−$17.1M
Capital expenditures
$38,109
Free cash flow
−$17.2M
Returned to shareholders
—
Change in cash
$6.2M
cash at year-end $11.0M
Share issuance (net): $28.5MShare issuance (net)$28.5MShares issued: $28.5MShares issued$28.5MOther financing: $31.6MOther financing$31.6M · 55%Cash used in operations: $17.1MCash used in operations$17.1M · 30%Debt repayment: $2.0MDebt repayment$2.0M · 4%Added to cash: $6.2MAdded to cash$6.2M · 11%Capital expenditures: $38,109Capital expenditures$38,109 · 0%$57.0M
Cash from operations
−$17.1M
Share buybacks (net)
+$28.5M
Net borrowing (repayment)
−$2.0M
Shares issued
+$28.5M
Other financing
−$31.6M
Change in cash
$6.2M

Drawn to scale: where the cash came from and how it was used. Hover for values.

CVM operating cash flow, capex and free cash flow

Operating cash flowCapital expendituresFree cash flowFCF margin (right axis)

CVM cash flow trends, FY2016–FY2025

CEL-SCI Corporation cash flow trends
MetricTrendThenLatestChange
Operating cash flow−$23.1MFY2016−$17.1MFY2025—
Capital expenditures$34,224FY2016$38,109FY2025+1.2%/yr
Free cash flow−$23.1MFY2016−$17.2MFY2025—
Free cash flow margin−8,109.6%FY2016−3,216.8%FY2020+4,892.8 pts
Stock-based compensation$2.3MFY2016$2.9MFY2025+2.7%/yr
Dividends paid$0FY2017$0FY2018—
Share buybacks (net)$0FY2016$0FY2025—
Capex / revenue12.0%FY2016482.4%FY2020+470.4 pts

Change is the average annual growth (CAGR) or the difference between the first and latest year.

CVM cash flow by activity

OperatingInvestingFinancingChange in cash

CVM net income vs operating cash flow

Net incomeOperating cash flow

Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).

CVM cash flow statement

CEL-SCI Corporation annual cash flow statement
FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating activities
Net income−$25.4M−$26.9M−$32.2M−$36.7M−$36.4M−$30.3M−$22.1M−$31.8M−$14.4M−$11.5M
Depreciation & amortization$3.9M$4.0M$4.0M$3.8M$2.2M$2.2M$633,529$650,131$632,915$150,243
Stock-based compensation$2.9M$4.3M$7.1M$12.2M$13.9M$10.3M$4.6M$2.9M$1.5M$2.3M
Change in working capital$1.2M−$1.2M−$1.8M$2.5M−$483,474−$1.2M−$4.5M−$2.7M$6.8M−$779,415
Other non-cash items$363,348$1.1M$15,292−$59,101$1.9M$3.8M$5.1M$17.6M−$8.3M−$13.3M
Cash from operating activities−$17.1M−$18.8M−$22.8M−$18.2M−$18.8M−$15.3M−$16.3M−$13.4M−$13.8M−$23.1M
Investing activities
Capital expenditures−$38,109−$94,875−$372,262−$637,892−$9.0M−$2.7M−$335,839−$58,140−$17,002−$34,224
Investments (net)—−$108,086−$372,262$6.2M−$6.1M−$2.7M−$335,839−$58,140−$17,002−$34,224
Acquisitions & other investing$0$94,875$372,262−$22,741$0$2.7M$335,839$58,140$17,002$34,224
Cash from investing activities−$38,109−$108,086−$372,262$5.5M−$15.2M−$2.7M−$335,839−$58,140−$17,002−$34,224
Financing activities
Dividends paid———————$0$0—
Share repurchases & issuance (net)$28.5M$23.7M$7.0M$131,060$54.0M$27.3M$14.8M$21.4M$10.5M$21.4M
Net borrowing (repayment)−$2.0M−$1.8M−$1.6M−$1.4M−$1.1M−$800,241$158,243−$6,312$2.7M−$8,213
Shares issued$28.5M$23.7M$6.6M$0$47.4M$14.0M$12.9M$11.6M$0$0
Other financing−$31.6M−$26.0M−$7.3M$617,009−$45.7M−$15.5M−$13.1M−$11.6M$0−$1.1M
Cash from financing activities$23.4M$19.5M$4.7M−$638,426$54.5M$25.0M$14.8M$21.4M$13.3M$20.3M
Summary
Net change in cash$6.2M$592,438−$18.5M−$13.4M$20.6M$7.1M−$1.9M$7.9M−$548,558−$2.8M
Cash at end of period$11.0M$4.7M$4.1M$22.7M$36.1M$15.5M$8.4M$10.3M$2.4M$2.9M
Free cash flow−$17.2M−$18.9M−$23.2M−$18.9M−$27.8M−$18.0M−$16.7M−$13.4M−$13.8M−$23.1M
Free cash flow margin—————−3,216.8%−3,599.4%−2,821.9%−20,007.1%−8,109.6%
Capex / revenue—————482.4%72.6%12.2%24.6%12.0%

Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.

CVM cash generation

In fiscal 2025 (ended September 30, 2025), CEL-SCI generated -$17.1 million of cash from operations and spent $0.0 million on capital expenditures, leaving free cash flow of -$17.2 million. Cash and equivalents rose by $6.2 million over the year.

Related: CVM income statement, CVM balance sheet. See the CVM stock overview for the latest quote and news.

CVM cash flow FAQ

What is CEL-SCI's free cash flow?

CEL-SCI's free cash flow was -$17.2 million in fiscal 2025: -$17.1 million of operating cash flow minus $0.0 million of capital expenditures It was -$18.9 million a year earlier..

How much cash does CEL-SCI generate from operations?

CEL-SCI generated -$17.1 million of cash from operating activities in fiscal 2025.

How much does CEL-SCI spend on capital expenditures?

CEL-SCI spent $0.0 million on capital expenditures in fiscal 2025, compared with $0.1 million the year before.

Biotechnology: cash flow